|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: H4C3 |
Gene summary for H4C3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | H4C3 | Gene ID | 8364 |
| Gene name | H4 clustered histone 3 | |
| Gene Alias | H4-16 | |
| Cytomap | 6p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | B2R4R0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8364 | H4C3 | CA_HPV_1 | Human | Cervix | CC | 5.54e-05 | -1.92e-01 | 0.0264 |
| 8364 | H4C3 | CCI_1 | Human | Cervix | CC | 2.20e-18 | -9.64e-01 | 0.528 |
| 8364 | H4C3 | CCI_2 | Human | Cervix | CC | 4.89e-17 | -9.64e-01 | 0.5249 |
| 8364 | H4C3 | CCI_3 | Human | Cervix | CC | 8.94e-24 | -9.64e-01 | 0.516 |
| 8364 | H4C3 | CCII_1 | Human | Cervix | CC | 6.15e-32 | -9.64e-01 | 0.3249 |
| 8364 | H4C3 | Tumor | Human | Cervix | CC | 1.28e-60 | -9.64e-01 | 0.1241 |
| 8364 | H4C3 | sample1 | Human | Cervix | CC | 3.74e-27 | -9.64e-01 | 0.0959 |
| 8364 | H4C3 | sample3 | Human | Cervix | CC | 3.95e-61 | -9.64e-01 | 0.1387 |
| 8364 | H4C3 | H2 | Human | Cervix | HSIL_HPV | 3.71e-62 | -9.64e-01 | 0.0632 |
| 8364 | H4C3 | L1 | Human | Cervix | CC | 9.56e-35 | -9.64e-01 | 0.0802 |
| 8364 | H4C3 | T1 | Human | Cervix | CC | 6.18e-55 | -9.64e-01 | 0.0918 |
| 8364 | H4C3 | T2 | Human | Cervix | CC | 3.24e-16 | -9.64e-01 | 0.0709 |
| 8364 | H4C3 | T3 | Human | Cervix | CC | 1.32e-59 | -9.64e-01 | 0.1389 |
| 8364 | H4C3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.57e-28 | 5.32e-01 | 0.0155 |
| 8364 | H4C3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.63e-22 | 6.67e-01 | -0.1808 |
| 8364 | H4C3 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.22e-05 | 3.08e-01 | 0.0216 |
| 8364 | H4C3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.28e-25 | 8.32e-01 | -0.0811 |
| 8364 | H4C3 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.64e-09 | 5.85e-01 | -0.1088 |
| 8364 | H4C3 | HTA11_347_2000001011 | Human | Colorectum | AD | 9.00e-40 | 1.28e+00 | -0.1954 |
| 8364 | H4C3 | HTA11_411_2000001011 | Human | Colorectum | SER | 6.42e-18 | 1.33e+00 | -0.2602 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
| GO:004563710 | Cervix | CC | regulation of myeloid cell differentiation | 48/2311 | 210/18723 | 1.49e-05 | 2.93e-04 | 48 |
| GO:00063257 | Cervix | CC | chromatin organization | 78/2311 | 409/18723 | 5.40e-05 | 8.02e-04 | 78 |
| GO:00063381 | Cervix | CC | chromatin remodeling | 45/2311 | 255/18723 | 8.33e-03 | 4.30e-02 | 45 |
| GO:003009915 | Cervix | HSIL_HPV | myeloid cell differentiation | 36/737 | 381/18723 | 1.19e-06 | 5.62e-05 | 36 |
| GO:190370613 | Cervix | HSIL_HPV | regulation of hemopoiesis | 35/737 | 367/18723 | 1.35e-06 | 6.21e-05 | 35 |
| GO:004563715 | Cervix | HSIL_HPV | regulation of myeloid cell differentiation | 22/737 | 210/18723 | 2.97e-05 | 8.57e-04 | 22 |
| GO:0030099 | Colorectum | AD | myeloid cell differentiation | 119/3918 | 381/18723 | 1.24e-06 | 4.01e-05 | 119 |
| GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
| GO:1903706 | Colorectum | AD | regulation of hemopoiesis | 99/3918 | 367/18723 | 3.08e-03 | 2.28e-02 | 99 |
| GO:0045637 | Colorectum | AD | regulation of myeloid cell differentiation | 61/3918 | 210/18723 | 3.17e-03 | 2.35e-02 | 61 |
| GO:0006338 | Colorectum | AD | chromatin remodeling | 70/3918 | 255/18723 | 7.44e-03 | 4.53e-02 | 70 |
| GO:00063251 | Colorectum | SER | chromatin organization | 89/2897 | 409/18723 | 4.15e-04 | 6.17e-03 | 89 |
| GO:00300991 | Colorectum | SER | myeloid cell differentiation | 80/2897 | 381/18723 | 2.28e-03 | 2.18e-02 | 80 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05322 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
| hsa053221 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |